Trial reportJournal of the American Heart Association2026
Total Clinical Event Burden With Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation and Stable Coronary Artery Disease: Insights From the EPIC-CAD Trial.
Trial report in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral anticoagulation is essential for stroke prevention in atrial fibrillation, whereas antiplatelet therapy remains standard for coronary artery disease (CAD), raising concerns about bleeding when both are combined. The effect of these regimens on recurrent events, reflecting cumulative disease burden, has not been fully evaluated.
methodsThis post hoc analysis of the EPIC-CAD (Edoxaban Versus Edoxaban With Antiplatelet Agent in Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial included 1040 patients with atrial fibrillation and stable CAD randomized to edoxaban monotherapy or edoxaban plus a single antiplatelet agent. The primary end point was the total number of net adverse clinical events at 12 months.
resultsOver a median follow-up of 12.1 months, 155 total events occurred (123 first, 32 subsequent). Event rates were lower with edoxaban monotherapy than with dual therapy (9.4 versus 19.8 per 100 person-years; incidence rate ratio, 0.47 [95% CI, 0.34-0.67]). Monotherapy reduced first events (incidence rate ratio, 0.46 [95% CI, 0.32-0.68]) and showed a lower cumulative hazard of total events (hazard ratio, 0.48 [95% CI, 0.32-0.71];
conclusionsEdoxaban monotherapy significantly reduced the overall burden of clinical events compared with dual antithrombotic therapy in patients with atrial fibrillation and stable CAD. Bleeding complications were more frequent than ischemic events, emphasizing the need to minimize bleeding risk in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.